PRTA SEC-Einreichungen - Prothena Corporation plc- Jahresbericht, Proxy Statement, Prospekt

Basisstatistiken

LEI	5299009ZXQ8NIIJ8OL30
CIK	1559053

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Prothena Corporation plc

SEC Filings (Chronological Order)

Auf dieser Seite finden Sie eine vollständige, chronologische Liste der SEC-Einreichungen, mit Ausnahme der Eigentumseinreichungen, die wir an anderer Stelle bereitstellen.

May 15, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 PROTHENA CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2026 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 7, 2026	EX-99.1	March 31, December 31, 2026 2025 Assets Cash and cash equivalents $ 329,462 $ 307,531 Prepaid expenses and other current assets 9,739 7,662 Total current assets 339,201 315,193 Property and equipment, net 1,960 2,144 Operating lease right-of-use asse Exhibit 99.1 PRESS RELEASE Prothena Reports First Quarter 2026 Financial Results and Business Highlights •Net cash provided by operating and investing activities was $28.9 million for the first quarter of 2026; quarter-end cash and restricted cash position was $330.3 million •Prothena updates projected full year 2026 net cash used in operating and investing actives to be $18 to $23 million (versus
May 7, 2026	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMPANY
May 7, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 PROTHENA CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2026 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporati
March 27, 2026	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
March 27, 2026	ARS	ARS +-/# )-+-/$)+' -;=?IJ;H;:?D$H;B7D: )E .?H%E>D-E=;HIEDRI,K7O BE9A "H7D:7D7B E9AB7D:I K8B?D 1& $H;B7D: )/$ !))0'" ) -'( /$)"! .#- #' -./* # '*)(4 1FK?<0?8IF=0?8IZF= -IFK?GLIGFJ<F=J?8IMFK< K?<8GGF@EKD@JK<; GL9C@:8::FLEK@E>=@ID=FI@KJ=@J:8CP<8I!<:MFK< K?< FDG8EP[JF8I;F=!@I<:KFIJ 8:K@E>K?IFL>
March 27, 2026	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
February 27, 2026	EX-10.9(B)	FIRST AMENDMENT TO THE PROTHENA CORPORATION PLC 2018 LONG TERM INCENTIVE PLAN Exhibit 10.9(b) FIRST AMENDMENT TO THE PROTHENA CORPORATION PLC 2018 LONG TERM INCENTIVE PLAN This First Amendment (this “First Amendment”) to the Prothena Corporation plc 2018 Long Term Incentive Plan (“2018 LTIP”), was made and adopted by the Board of Directors (“Board”) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the “Company”), on February 25, 202
February 27, 2026	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35676 PROTHENA CORPORATION PUB
February 27, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2026 PROTHENA CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2026 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
February 27, 2026	EX-FILING FEES	Security Type Calculation of Filing Fee Tables S-3 PROTHENA CORP PUBLIC LTD CO Table 1: Newly Registered and Carry Forward Securities ☐Not Applicable Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effective Date Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to be Paid Fees Previously Paid 1 Equity Ordinary Shares, $0.
February 27, 2026	EX-21.1	List of Subsidiaries Subsidiary Name Jurisdiction of Incorporation or Organization Prothena Biosciences Limited Ireland Prothena Biosciences Inc Delaware Prothena Finance Inc Delaware Othair Prothena Limited Ireland Prothena Pharma Limited Ireland Pr Exhibit 21.1 List of Subsidiaries Subsidiary Name Jurisdiction of Incorporation or Organization Prothena Biosciences Limited Ireland Prothena Biosciences Inc Delaware Prothena Finance Inc Delaware Othair Prothena Limited Ireland Prothena Pharma Limited Ireland Prothena Platform Technologies Limited Ireland
February 27, 2026	EX-4.2	DESCRIPTION OF REGISTRANT’S SECURITIES EXHIBIT 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES This description is summarized from, and qualified in its entirety by reference to, our Amended and Restated Memorandum and Articles of Association (our “Constitution”), each of which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this exhibit is a part. In this exhibit, unless the context otherwise requires,
February 27, 2026	POS AM	As filed with the Securities and Exchange Commission on February 27, 2026 POS AM Table of Contents As filed with the Securities and Exchange Commission on February 27, 2026 Registration No.
February 27, 2026	EX-10.4(B)	AMENDMENT NUMBER ONE GLOBAL LICENSE AGREEMENT EXHIBIT 10.4(b) CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. AMENDMENT NUMBER ONE TO GLOBAL LICENSE AGREEMENT THIS AMENDMENT NUMBER ONE TO GLOBAL LICENSE AGREEMENT (this “Amendment”) is effective as of October 15, 2025 (the “Amendment Eff
February 27, 2026	EX-99.1	Prothena Announces up to $100 Million Share Repurchase Plan EXHIBIT 99.1 PRESS RELEASE Prothena Announces up to $100 Million Share Repurchase Plan DUBLIN, Ireland, February 27, 2026 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that its Board of Directors has authorized a Share Repurchase Plan under which
February 27, 2026	POSASR	As filed with the Securities and Exchange Commission on February 27, 2026 POSASR Table of Contents As filed with the Securities and Exchange Commission on February 27, 2026 Registration No.
February 19, 2026	EX-99.1	December 31, 2025 2024 Assets Cash and cash equivalents $ 307,531 $ 471,388 Prepaid expenses and other current assets 7,662 14,024 Total current assets 315,193 485,412 Property and equipment, net 2,144 3,081 Operating lease right-of-use assets 8,125 Exhibit 99.1 PRESS RELEASE Prothena Reports Fourth Quarter and Full Year 2025 Financial Results, and Provides Financial Guidance and Business Highlights •Net cash used in operating and investing activities was $23.3 million and $163.7 million for the fourth quarter and full year of 2025, respectively; quarter-end cash and restricted cash position was $308.4 million •Prothena expects the full year
February 19, 2026	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 PROTHENA CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 19, 2026 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
December 12, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2025 PROTHENA CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 10, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
November 19, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 PROTHENA CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 19, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
November 6, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Pro
November 6, 2025	EX-99.1	September 30, December 31, 2025 2024 Assets Cash and cash equivalents $ 330,843 $ 471,388 Prepaid expenses and other current assets 9,131 14,024 Total current assets 339,974 485,412 Property and equipment, net 2,463 3,081 Operating lease right-of-use Exhibit 99.1 PRESS RELEASE Prothena Reports Third Quarter 2025 Financial Results and Business Highlights •Net cash used in operating and investing activities was $40.6 million and $140.4 million for the third quarter and first nine months of 2025, respectively; quarter-end cash and restricted cash position was $331.7 million •Roche to initiate the Phase 3 PARAISO clinical trial evaluating prasinez
November 6, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COM
November 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 PROTHENA CORPORA UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorp
October 7, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
October 7, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commi
September 25, 2025	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commi
August 27, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 PROTHENA CORPORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 27, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or other jurisdiction of incorpo
August 27, 2025	EX-99.1	Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program EX-99.1 Exhibit 99.1 PRESS RELEASE Prothena Provides Update on PRX012 and Announces Results from the Phase 1 ASCENT Clinical Program • As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibody • Phase 1 ASCENT clinical program established proof-of-mechanism for PRX012 as a once-monthly, subc
August 8, 2025	EX-FILING FEES	Calculation of Filing Fee Tables Form S-8 (Form Type) Prothena Corporation Public Limited Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Prothena Corporation Public Limited Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Ordinary Shares, par value $0.
August 8, 2025	S-8	As filed with the Securities and Exchange Commission on August 8, 2025 As filed with the Securities and Exchange Commission on August 8, 2025 Registration No.
August 6, 2025	EX-99.1	Prothena Announces that Novo Nordisk Will Advance Coramitug (formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy EX-99.1 Exhibit 99.1 PRESS RELEASE Prothena Announces that Novo Nordisk Will Advance Coramitug (formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy • Coramitug is a potential first-in-class amyloid depleter antibody for the treatment of ATTR amyloidosis with cardiomyopathy1-3 • Novo Nordisk successfully completed a Phase 2 trial with coramitug and is expected to init
August 6, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 PROTHENA CORPORATI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or other jurisdiction of incorpor
August 4, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 PROTHENA CORPORATI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpor
August 4, 2025	EX-99.1	June 30, December 31, 2025 2024 Assets Cash and cash equivalents $ 371,435 $ 471,388 Prepaid expenses and other current assets 14,040 14,024 Total current assets 385,475 485,412 Property and equipment, net 2,690 3,081 Operating lease right-of-use ass Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2025 Financial Results and Business Highlights •Net cash used in operating and investing activities was $46.4 million in the second quarter and net cash used in operating and investing activities was $99.8 million for the first six months of 2025; quarter-end cash and restricted cash position was $372.3 million •Prothena expects to convene
August 4, 2025	EX-10.2	Award Agreement between Prothena Corporation plc and its Named Executive Officers under the Prothena Corporation plc 2018 Long Term Incentive Plan Form of Restricted Share Unit Award Agreement between Prothena Corporation plc and Registrant’s Named Executive Officers PROTHENA CORPORATION PLC 2018 LONG TERM INCENTIVE PLAN Restricted Share Unit Award Agreement – Cover Sheet Prothena Corporation plc, an Irish public limited company (the “Company”), hereby grants a Restricted Share Unit Award with respect to Shares to the individual named below.
August 4, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMPANY
July 30, 2025	EX-10.1	Form of Employment Agreement EX-10.1 Exhibit 10.1 Form of Employment Agreement This Employment Agreement (the “Agreement”), dated as of [•], is made by and between Prothena Biosciences Inc, a Delaware corporation (the “Company”), and [•] (“Executive” and, together with the Company, the “Parties”) effective as of [•] (the “Effective Date”). RECITALS WHEREAS, the Company desires to assure itself of the continued services of Exe
July 30, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 PROTHENA CORPORATIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or other jurisdiction of incorpora
June 18, 2025	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 PROTHENA CORPORATIO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or other jurisdiction of incorpora
June 16, 2025	EX-99.1	Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson’s Disease Exhibit 99.1 PRESS RELEASE Prothena’s Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson’s Disease • Data from Phase IIb PADOVA study and longer term follow-up data suggest clinical benefit on top of symptomatic treatment in early-stage Parkinson’s disease • Prasinezumab is a potential first-in-class anti-alpha-synuclein antibody, targeting a known biologica
June 16, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or other jurisdiction of incorpora
May 23, 2025	EX-99.1	Prothena Announces Phase 3 Exhibit 99.1 PRESS RELEASE Prothena Announces Phase 3 AFFIRM-AL Clinical Trial for Birtamimab in Patients with AL Amyloidosis Did Not Meet Primary Endpoint • Birtamimab did not meet the primary endpoint of time to all-cause mortality or the secondary endpoints • Birtamimab development will be discontinued, including stopping the open label extension of the AFFIRM-AL clinical trial • Company will d
May 23, 2025	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or other jurisdiction of incorporat
May 16, 2025	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 16, 2025	EX-10.1	Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan Exhibit 10.1 SIXTH AMENDMENT TO THE PROTHENA CORPORATION PLC 2018 LONG TERM INCENTIVE PLAN This Sixth Amendment (this “Sixth Amendment”) to the Prothena Corporation plc 2018 Long Term Incentive Plan, as amended (“2018 LTIP”), was made and adopted by the Board of Directors (“Board”) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the “Company”), on Februar
May 8, 2025	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMPANY
May 8, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporati
May 8, 2025	EX-99.1	March 31, December 31, 2025 2024 Assets Cash and cash equivalents $ 417,935 $ 471,388 Prepaid expenses and other current assets 18,238 14,024 Total current assets 436,173 485,412 Property and equipment, net 2,871 3,081 Operating lease right-of-use as Exhibit 99.1 PRESS RELEASE Prothena Reports First Quarter 2025 Financial Results and Business Highlights •Net cash used in operating and investing activities was $53.4 million in the first quarter of 2025; quarter-end cash and restricted cash position was $418.8 million •Topline results expected in 2Q 2025 from the confirmatory Phase 3 AFFIRM-AL clinical trial of birtamimab in patients with Mayo S
March 28, 2025	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
March 28, 2025	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
February 27, 2025	EX-19.1	Corporation plc Insider Trading Compliance Policy Exhibit 19.1 PROTHENA CORPORATION PLC INSIDER TRADING COMPLIANCE POLICY I. PURPOSE It is illegal for any employee, officer or director of Prothena Corporation plc or any of its subsidiaries (the “Company”) to trade in the securities of Prothena Corporation plc while in the possession of material non-public information about the Company. A “trade” as referenced in this Insider Trading Compliance Po
February 27, 2025	EX-10.11(B)	First through Fifth Amendments to the Prothena Corporation plc 2018 Long Term Incentive Plan Exhibit 10.11(b) FIRST AMENDMENT TO THE PROTHENA CORPORATION PLC 2018 LONG TERM INCENTIVE PLAN This First Amendment (this “First Amendment”) to the Prothena Corporation plc 2018 Long Term Incentive Plan (“2018 LTIP”), was made and adopted by the Board of Directors (“Board”) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the “Company”), on February 25, 20
February 27, 2025	EX-4.2	Description of Registrant’s Securities EXHIBIT 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES This description is summarized from, and qualified in its entirety by reference to, our Amended and Restated Memorandum and Articles of Association (our “Constitution”), each of which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this exhibit is a part. In this exhibit, unless the context otherwise requires,
February 27, 2025	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35676 PROTHENA CORPORATION PUB
February 27, 2025	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Subsidiary Name Jurisdiction of Incorporation or Organization Prothena Biosciences Limited Ireland Prothena Biosciences Inc Delaware Prothena Finance Inc Delaware Othair Prothena Limited Ireland Prothena Pharma Limited Ireland Prothena Platform Technologies Limited Ireland
February 20, 2025	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 20, 2025 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
February 20, 2025	EX-99.1	December 31, 2024 2023 Assets Cash and cash equivalents $ 471,388 $ 618,830 Restricted cash, current — 1,352 Prepaid expenses and other current assets 14,024 19,100 Total current assets 485,412 639,282 Property and equipment, net 3,081 3,836 Operatin Exhibit 99.1 PRESS RELEASE Prothena Reports Fourth Quarter and Full Year 2024 Financial Results, and Provides Financial Guidance and Business Highlights •Net cash used in operating and investing activities was $47.8 million in the fourth quarter and $150.3 million for the full year of 2024; quarter-end cash and restricted cash position was $472.2 million •The company expects cash guidance for the
February 10, 2025	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Prothena Corporation Public Limited Company is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
January 3, 2025	EX-99.1 AGREEMENT	AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection wi
December 30, 2024	8-K	Current Report UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 29, 2024 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
November 14, 2024	SC 13G/A	PRTA / Prothena Corporation plc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment SC 13G/A 1 prta13gasep24.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5) PROTHENA CORP PLC (Name of Issuer) COMMON STOCK (Title of Class of Securities) G72800108 (CUSIP NUMBER) September 30, 2024 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule purs
November 13, 2024	SC 13G/A	PRTA / Prothena Corporation plc / SCULLY WILLIAM P - SC 13G/A Passive Investment SC 13G/A 1 d853309dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) * Prothena Corporation PLC (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) G72800108 (CUSIP Number) Diana L. Hayes, Esq. Trenam Law 2700 Bank of America Plaza Tampa, Florida 33602 8
November 13, 2024	SC 13G/A	PRTA / Prothena Corporation plc / Fennell Todd W. - SC 13G/A Passive Investment SC 13G/A 1 d853303dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) * Prothena Corporation PLC (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) G72800108 (CUSIP Number) Diana L. Hayes, Esq. Trenam Law 2700 Bank of America Plaza Tampa, Florida 33602 8
November 12, 2024	EX-10.2	, between Prothena Biosciences Inc and Chad J. Swanson, Ph.D. September 27, 2024 Dear Chad: I am pleased to confirm your promotion and appointment as Chief Development Officer by the Board of Directors of Prothena Corporation plc (“Prothena” or the “Company”). In this position, you will report to Gene Kinney (President and CEO), although your duties, title and reporting relationship may change, based on the Company’s needs and prioriti
November 12, 2024	EX-10.1	, between Prothena Biosciences Inc and Dennis J. Selkoe Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is effective as of October 1, 2024 (the “Effective Date”) and is made by and between Dennis J. Selkoe, M.D., an individual (“Consultant”), and Prothena Biosciences Inc, a Delaware corporation with offices at 1800 Sierra Point Parkway, Brisbane, CA 94005, U.S.A. (“Prothena”). Consultant and Prothena may each be referred
November 12, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COM
November 12, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 PROTHENA CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
November 12, 2024	EX-99.1	Three Months Ended September 30, Exhibit 99.1 PRESS RELEASE Prothena Reports Third Quarter 2024 Financial Results and Business Highlights •Net cash used in operating and investing activities was $102.5 million and $102.5 million for the third quarter and first nine months of 2024, respectively; quarter-end cash and restricted cash position was $520.1 million •PRX012, a potential single-injection once-monthly subcutaneous treatmen
November 8, 2024	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Prothena Corporation Public Limited Company is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
November 8, 2024	SC 13G	PRTA / Prothena Corporation plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Prothena Corporation Public Limited Company (Name of Issuer) Ordinary Shares (Title of Class of Securities) G72800108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Chec
November 7, 2024	SC 13G/A	PRTA / Prothena Corporation plc / WELLINGTON MANAGEMENT GROUP LLP - SEC SCHEDULE 13G Passive Investment SC 13G/A 1 SEC13GFiling.htm SEC SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1 )* Prothena Corporation Public Limited Company (Name of Issuer) Ordinary Shares (Title of Class of Securities) G72800108 (CUSIP Number) October 31, 2024 (Date of Event Which Requires Filing of this Statement) Ch
November 7, 2024	EX-99	JOINT FILING AGREEMENT JOINT FILING AGREEMENT The undersigned hereby agree that this Schedule 13G (the “Schedule 13G”) with respect to the common stock of Prothena Corporation Public Limited Company is, and any additional amendment thereto signed by each of the undersigned shall be, filed on behalf of each undersigned pursuant to and in accordance with the provisions of 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to the Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint filing agreements.
October 18, 2024	SC 13G/A	PRTA / Prothena Corporation plc / STATE STREET CORP Passive Investment SC 13G/A 1 ProthenaCorpPLC.htm SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* PROTHENA CORP PLC (Name of Issuer) COMMON STOCK (Title of Class of Securities) G72800108 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to
September 27, 2024	8-K	Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 23, 2024 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Inco
September 27, 2024	EX-99.1	Prothena Announces Leadership Team Updates Exhibit 99.1 PRESS RELEASE Prothena Announces Leadership Team Updates •Chad J. Swanson, Ph.D., appointed Chief Development Officer and will lead clinical development and medical functions •Hideki Garren, MD, Ph.D., Chief Medical Officer, will pursue an opportunity at a large pharmaceutical company to lead a global product development division DUBLIN, Ireland, September 27, 2024 - Prothena Corporat
August 8, 2024	EX-99.1	June 30, December 31, 2024 2023 Assets Cash and cash equivalents $ 564,124 $ 618,830 Restricted cash, current — 1,352 Prepaid expenses and other current assets 21,854 19,100 Total current assets 585,978 639,282 Property and equipment, net 3,486 3,836 Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2024 Financial Results and Business Highlights •Net cash provided by operating and investing activities was $15.8 million in the second quarter and net cash used by operating and investing activities was $57.3 million for the first six months of 2024; quarter-end cash and restricted cash position was $565.0 million •Revised year-end cash g
August 8, 2024	S-8	As filed with the Securities and Exchange Commission on August 8, 2024 As filed with the Securities and Exchange Commission on August 8, 2024 Registration No.
August 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpor
August 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMPANY
August 8, 2024	EX-FILING FEES	Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Prothena Corporation Public Limited Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity(2) Ordinary Shares, par value $0.
August 8, 2024	EX-10.3	, by and between Prothena Biosciences Limited and Celgene Switzerland LLC Exhibit 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. GLOBAL LICENSE AGREEMENT by and among PROTHENA BIOSCIENCES LIMITED and CELGENE SWITZERLAND LLC Dated as of May 24, 2024 DB1/ 145706242.22 LIST OF SCHEDULES SCHEDULE 1.32 ENABLED AN
May 28, 2024	8-K	Entry into a Material Definitive Agreement, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2024 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 17, 2024	EX-10.1	Fifth Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan Exhibit 10.1 FIFTH AMENDMENT TO THE PROTHENA CORPORATION PLC 2018 LONG TERM INCENTIVE PLAN This Fifth Amendment (this “Fifth Amendment”) to the Prothena Corporation plc 2018 Long Term Incentive Plan, as amended (“2018 LTIP”), was made and adopted by the Board of Directors (“Board”) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the “Company”), on Februar
May 17, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 PROTHENA CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 8, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2024 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporati
May 8, 2024	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMPANY
May 8, 2024	EX-99.1	March 31, December 31, 2024 2023 Assets Cash and cash equivalents $ 546,512 $ 618,830 Restricted cash, current 1,352 1,352 Prepaid expenses and other current assets 18,004 19,100 Total current assets 565,868 639,282 Property and equipment, net 3,672 Exhibit 99.1 PRESS RELEASE Prothena Reports First Quarter 2024 Financial Results and Business Highlights •Net cash used in operating and investing activities was $73.2 million in the first quarter of 2024; quarter-end cash and restricted cash position was $548.7 million •Advanced potential best-in-class Alzheimer’s disease portfolio: initial data supportive of ongoing Phase 1 clinical trial for PR
May 8, 2024	EX-10.2	Side Letters to Master Collaboration Agreement, dated as of March 20, 2018, between Prothena Biosciences Limited and Celgene Switzerland LLC Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. Bristol Myers Squibb PO. Box 4000, Route 206 & Province Line Road, Princeton, NJ 08543-4000 SENT BY EMAIL AS PDF January 16, 2024 Prothena Biosciences Limited 77 Sir John Rogerson’
May 8, 2024	EX-10.1	Offer letter, dated February 12, 2024, between Prothena Biosciences Inc and David A. Ford Exhibit 10.1 David Ford February 12, 2024 Dear David: I am pleased to confirm this offer for you to join Prothena Biosciences Inc (“Prothena” or the “Company”). We are confident in your knowledge, expertise and judgment, and believe your performance will meet our team’s high-quality objectives and standards. Your start date will be March 1, 2024, and, subject to the discretion of the Prothena Corp
March 29, 2024	ARS	ARS PROTHENA CORPORATION PLC Registered in Ireland - No. 518146 77 Sir John Rogerson’s Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 14, 2024 To the Shareholders of Prothena Corporation plc: NOTICE IS HEREBY GIVEN that the Annual General Meeting of Shareholders (the ‘‘Annual Meeting’’) of Proth- ena Corporation plc,
March 29, 2024	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
March 29, 2024	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
February 22, 2024	EX-10.23	Amendments to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan Exhibit 10.23 FIRST AMENDMENT TO THE PROTHENA CORPORATION PLC 2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN This First Amendment (this “First Amendment”) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (“2020 EIIP”), was made and adopted by the Board of Directors (“Board”) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the “Company”
February 22, 2024	EX-4.2	Exhibit 4.2 EXHIBIT 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES This description is summarized from, and qualified in its entirety by reference to, our Amended and Restated Memorandum and Articles of Association (our “Constitution”), each of which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this exhibit is a part. In this exhibit, unless the context otherwise requires,
February 22, 2024	EX-FILING FEES	Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-3ASR (Form Type) Prothena Corporation Public Limited Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Newly Registered Securities Fees to Be Paid Equity Ordinary Shares, par value $0.
February 22, 2024	S-3ASR	As filed with the Securities and Exchange Commission on February 22, 2024 Table of Contents As filed with the Securities and Exchange Commission on February 22, 2024 Registration No.
February 22, 2024	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Subsidiary Name Jurisdiction of Incorporation or Organization Prothena Biosciences Limited Ireland Prothena Biosciences Inc Delaware Prothena Finance Inc Delaware Othair Prothena Limited Ireland Prothena Pharma Limited Ireland Prothena Platform Technologies Limited Ireland
February 22, 2024	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35676 PROTHENA CORPORATION PUB
February 22, 2024	EX-1.3	Amendment, dated February 22, 2024, to Equity Distribution Agreement. Exhibit 1.3 PROTHENA CORPORATION PLC AMENDMENT LETTER TO EQUITY DISTRIBUTION AGREEMENT February 22, 2024 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 CANTOR FITZGERALD & CO. 110 East 59th Street, 6th Floor New York, New York 10022 RBC CAPITAL MARKETS, LLC 200 Ve
February 22, 2024	EX-97	n Recoupment of Incentive Compensation Exhibit 97 PROTHENA CORPORATION PLC POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Board of Directors (the “Board”) of Prothena Corporation plc (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event of a restatement of financial results by the Company.
February 21, 2024	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
February 15, 2024	EX-99.1	December 31, 2023 2022 Assets Cash and cash equivalents $ 618,830 $ 710,406 Restricted cash, current 1,352 — Prepaid expenses and other current assets 19,100 8,692 Total current assets 639,282 719,098 Property and equipment, net 3,836 1,731 Operating Exhibit 99.1 PRESS RELEASE Prothena Reports Fourth Quarter and Full Year 2023 Financial Results, and Provides Financial Guidance and Business Highlights •Net cash used in operating and investing activities was $52.6 million in the fourth quarter and $136.7 million for the full year of 2023; quarter-end cash and restricted cash position was $621.0 million •The company expects cash guidance for the
February 15, 2024	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
February 14, 2024	SC 13G	PRTA / Prothena Corporation plc / SCULLY WILLIAM P - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Prothena Corporation PLC (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) G72800108 (CUSIP Number) Diana L. Hayes, Esq. Trenam Law 2700 Bank of America Plaza Tampa, Florida 33602 813-227-7433 (Name, Address and Tele
February 14, 2024	SC 13G	PRTA / Prothena Corporation plc / Fennell Todd W. - SC 13G Passive Investment SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Prothena Corporation PLC (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) G72800108 (CUSIP Number) Diana L. Hayes, Esq. Trenam Law 2700 Bank of America Plaza Tampa, Florida 33602 813-227-7433 (Name, Address and Tele
February 14, 2024	EX-99.A	LIMITED POWER OF ATTORNEY EX-99.A CUSIP No. G72800108 Schedule 13G Page 7 of 7 Pages EXHIBIT A LIMITED POWER OF ATTORNEY This Limited Power of Attorney (the “Power of Attorney”) is made and effective February 13, 2024, by and between Diana L. Hayes (the “Attorney”), an attorney and member in good standing of the Florida Bar of the State of Florida, whose principal office is located at 101 East Kennedy Boulevard, Suite 2700
February 14, 2024	SC 13G/A	PRTA / Prothena Corporation plc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) PROTHENA CORP PLC (Name of Issuer) COMMON STOCK (Title of Class of Securities) G72800108 (CUSIP NUMBER) December 31, 2023 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is
February 13, 2024	SC 13G/A	PRTA / Prothena Corporation plc / Avidity Partners Management LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.
February 9, 2024	SC 13G/A	PRTA / Prothena Corporation plc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.3 PROTHENA CORP PLC COMMON STOCK Cusip #G72800108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G72800108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 8,049,190 Item 6: 0 Item 7: 8,049,796 Item 8: 0 Item 9: 8,049,796 Item 11: 14.9
February 2, 2024	SC 13G/A	PRTA / Prothena Corporation plc / BlackRock Inc. Passive Investment ie00b91xrn20020224.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 9) PROTHENA CORPORATION PUBLIC LIMITED COMPANY - (Name of Issuer) Common Stock - (Title of Class of Securities) B91XRN2 - (SEDOL Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designa
January 24, 2024	SC 13G	PRTA / Prothena Corporation plc / STATE STREET CORP Passive Investment SC 13G 1 ProthenaCorpPLC.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 INITIAL FILING PROTHENA CORP PLC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) G72800108 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT T
January 8, 2024	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 PROTHENA CORPORAT UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpo
January 8, 2024	EX-99.1	Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs EX-99.1 Exhibit 99.1 PRESS RELEASE Prothena Provides Updates on PRX012, PRX123, Birtamimab and Portfolio Programs • Updates on PRX012 and PRX123 for treatment of Alzheimer’s disease, and on birtamimab for treatment of AL amyloidosis • Remain on track with partnered programs: Bristol Myers Squibb (BMS-986446 for the treatment of Alzheimer’s disease), Roche (Prasinezumab for the treatment of Parkins
November 2, 2023	EX-10.2	Global License Agreement, dated as of July 5, 2023, by and between Prothena Biosciences Limited and Celgene Switzerland LLC Exhibit 10.2 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. GLOBAL LICENSE AGREEMENT by and among PROTHENA BIOSCIENCES LIMITED and CELGENE SWITZERLAND LLC Dated as of July 5, 2023 TABLE OF CONTENTS LIST OF SCHEDULES SCHEDULE 1.27 EXISTING I
November 2, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COM
November 2, 2023	EX-10.1	, between Prothena Biosciences Inc and Dennis J. Selkoe Exhibit 10.1 CONSULTING AGREEMENT This Consulting Agreement (this “Agreement”) is effective as of October 1, 2023 (the “Effective Date”) and is made by and between Dennis J. Selkoe, M.D., an individual (“Consultant”), and Prothena Biosciences Inc, a Delaware corporation with offices at 331 Oyster Point Boulevard, South San Francisco, CA 94080, U.S.A. (“Prothena”). Consultant and Prothena may each
November 2, 2023	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2023 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorp
November 2, 2023	EX-99.1	September 30, December 31, 2023 2022 Assets Cash and cash equivalents $ 670,897 $ 710,406 Restricted cash, current 1,352 — Prepaid expenses and other current assets 18,355 8,692 Total current assets 690,604 719,098 Property and equipment, net 2,433 1 Exhibit 99.1 PRESS RELEASE Prothena Reports Third Quarter 2023 Financial Results and Business Highlights •Net cash provided by operating and investing activities was $9.1 million in the third quarter and net cash used in operating and investing activities was $84.1 million for the first nine months of 2023; quarter-end cash and restricted cash position was $673.1 million •Received $55 million paym
August 23, 2023	LETTER	LETTER United States securities and exchange commission logo August 23, 2023 Tran B. Nguyen Chief Financial Officer Prothena Corporation plc 77 Sir John Rogerson s Quay, Block C Grand Canal Docklands, Dublin 2, D02 VK60 Ireland Re: Prothena Corporation plc Form 10-Q for the Fiscal Quarter Ended March 31, 2023 File No. 001-35676 Dear Tran B. Nguyen: We have completed our review of your filing. We remind y
August 4, 2023	CORRESP	Prothena Corporation plc 77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands Dublin 2, D02 VK60, Ireland Prothena Corporation plc 77 Sir John Rogerson’s Quay, Block C Grand Canal Docklands Dublin 2, D02 VK60, Ireland August 4, 2023 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.
August 3, 2023	S-8	As filed with the Securities and Exchange Commission on August 3, 2023 S-8 As filed with the Securities and Exchange Commission on August 3, 2023 Registration No.
August 3, 2023	EX-99.1	June 30, December 31, 2023 2022 Assets Cash and cash equivalents $ 659,111 $ 710,406 Restricted cash, current 1,352 — Prepaid expenses and other current assets 16,640 8,692 Total current assets 677,103 719,098 Property and equipment, net 2,170 1,731 Exhibit 99.1 PRESS RELEASE Prothena Reports Second Quarter 2023 Financial Results and Business Highlights •Net cash used in operating and investing activities was $45.7 million in the second quarter and $93.2 million for the first six months of 2023; quarter-end cash and restricted cash position was $661.3 million •Revised year-end cash guidance to be approximately $600 million in cash, cash equiv
August 3, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMPANY
August 3, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 PROTHENA CORPORATI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 3, 2023 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpor
August 3, 2023	EX-FILING FEES	Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) Prothena Corporation Public Limited Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity(2) Ordinary Shares, par value $0.
July 25, 2023	LETTER	LETTER United States securities and exchange commission logo July 25, 2023 Tran B. Nguyen Chief Financial Officer Prothena Corporation plc 77 Sir John Rogerson s Quay, Block C Grand Canal Docklands, Dublin 2, D02 VK60 Ireland Re: Prothena Corporation plc Form 10-Q for the Fiscal Quarter Ended March 31, 2023 Filed May 4, 2023 File No. 001-35676 Dear Tran B. Nguyen: We have reviewed your filing and have th
July 10, 2023	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 5, 2023 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 19, 2023	EX-10.1	Fourth Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan. (6) EX-10.1 Exhibit 10.1 FOURTH AMENDMENT TO THE PROTHENA CORPORATION PLC 2018 LONG TERM INCENTIVE PLAN This Fourth Amendment (this “Third Amendment”) to the Prothena Corporation plc 2018 Long Term Incentive Plan, as amended (“2018 LTIP”), was made and adopted by the Board of Directors (“Board”) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the “Company”),
May 19, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 PROTHENA CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 16, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 PROTHENA CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2023 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 4, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 PROTHENA CORPORATION UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 4, 2023 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporati
May 4, 2023	EX-99.1	March 31, December 31, 2022 2023 2022 Assets Cash and cash equivalents $ 686,184 $ 710,406 Prepaid expenses and other current assets 14,159 8,692 Total current assets 700,343 719,098 Property and equipment, net 1,924 1,731 Operating lease right-of-us Exhibit 99.1 PRESS RELEASE Prothena Reports First Quarter 2023 Financial Results and Business Highlights •Net cash used in operating and investing activities was $47.5 million in the first quarter of 2023; quarter-end cash and restricted cash position was $688.4 million •Data reported in an oral presentation at AD/PD 2023 that PRX012, a potential best-in-class anti-amyloid beta antibody, demonstra
May 4, 2023	EX-10.1	Fourteenth Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan Exhibit 10.1 FOURTEENTH AMENDMENT TO THE PROTHENA CORPORATION PLC 2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN This Fourteenth Amendment (this “Fourteenth Amendment”) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (“2020 EIIP”), was made and adopted by the Board of Directors (“Board”) of Prothena Corporation plc, a public limited company organized under the laws of Ireland
May 4, 2023	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMPANY
April 28, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 PROTHENA CORPORATI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpor
March 31, 2023	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive Proxy State
March 31, 2023	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defi
March 31, 2023	ARS	ARS PROTHENA CORPORATION PLC Registered in Ireland - No. 518146 77 Sir John Rogerson's Quay, Block C, Grand Canal Docklands, Dublin 2, D02 VK60, Ireland NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD ON MAY 16, 2023 To the Shareholders of Prothena Corporation plc: NOTICE IS HEREBY GIVEN that the Annual General Meeting of Shareholders (the ‘‘Annual Meeting’’) of Prothena Corporationplc,anI
March 10, 2023	SC 13G/A	PRTA / Prothena Corporation plc / FMR LLC Passive Investment SCHEDULE 13G Amendment No.2 PROTHENA CORP PLC COMMON STOCK Cusip #G72800108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G72800108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 5,264,223 Item 6: 0 Item 7: 5,264,847 Item 8: 0 Item 9: 5,264,847 Item 11: 10.0
March 10, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 PROTHENA CORPORATI UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpor
February 28, 2023	EX-10.15(A)	Sublease, dated as of October 28, 2022, by and between Arcus Biosciences, Inc. and Prothena Biosciences Inc. Exhibit 10.15(a) SUBLEASE THIS SUBLEASE (this “Sublease”) is dated for reference purposes as of October 28, 2022 (the “Effective Date”), and is made by and between Arcus Biosciences, Inc., a Delaware corporation (“Sublessor”), and Prothena Biosciences Inc, a Delaware corporation (“Sublessee”). Sublessor and Sublessee hereby agree as follows: 1.Recitals: This Sublease is made with reference to the
February 28, 2023	EX-10.15(B)	Consent to Sublease Agreement, dated as of October 28, 2022, by and among HCP LS Brisbane, LLC, Arcus Biosciences, Inc., and Prothena Biosciences Inc. Exhibit 10.15(b) CONSENT TO SUBLEASE AGREEMENT THIS CONSENT TO SUBLEASE AGREEMENT (this "Agreement") is made as of October 28, 2022, by and among HCP LS BRISBANE, LLC, a Delaware limited liability company ("Landlord"), ARCUS BIOSCIENCES, INC., a Delaware corporation ("Tenant"), and PROTHENA BIOSCIENCES INC, a Delaware corporation ("Subtenant"). R E C I T A L S A.Reference is hereby made to that ce
February 28, 2023	EX-10.22	First through Thirteenth Amendments to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan Exhibit 10.22 FIRST AMENDMENT TO THE PROTHENA CORPORATION PLC 2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN This First Amendment (this “First Amendment”) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (“2020 EIIP”), was made and adopted by the Board of Directors (“Board”) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the “Company”
February 28, 2023	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35676 PROTHENA CORPORATION PUB
February 28, 2023	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Subsidiary Name Jurisdiction of Incorporation or Organization Prothena Biosciences Limited Ireland Prothena Biosciences Inc Delaware Prothena Finance Inc Delaware Othair Prothena Limited Ireland Prothena Pharma Limited Ireland Prothena Platform Technologies Limited Ireland
February 28, 2023	EX-4.2	Description of Registrant’s Securities EXHIBIT 4.2 DESCRIPTION OF REGISTRANT’S SECURITIES This description is summarized from, and qualified in its entirety by reference to, our Amended and Restated Memorandum and Articles of Association (our “Constitution”), each of which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this exhibit is a part. In this exhibit, unless the context otherwise requires,
February 23, 2023	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 PROTHENA CORPOR UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
February 23, 2023	EX-99.1	December 31, December 31, 2021 2022 2021 Assets Cash and cash equivalents $ 710,406 $ 579,094 Prepaid expenses and other current assets 8,692 5,715 Total current assets 719,098 584,809 Property and equipment, net 1,731 2,012 Operating lease right-of- Exhibit 99.1 PRESS RELEASE Prothena Reports Fourth Quarter and Full Year 2022 Financial Results, and Provides Financial Guidance and Business Highlights •Net cash used in operating and investing activities was $5.1 million in the fourth quarter and $109.3 million for the full year of 2022; quarter-end cash and restricted cash position was $712.6 million •Advanced potential best-in-class Alzheimer’
February 14, 2023	SC 13G/A	PRTA / Prothena Corp plc / Avidity Partners Management LP Passive Investment SC 13G/A 1 d990838113g-a.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Prothena Corporation Public Limited Company (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G72800108 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statem
February 14, 2023	SC 13G/A	PRTA / Prothena Corp plc / SCULLY WILLIAM P - SC 13G/A Passive Investment SC 13G/A 1 d423670dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1) * Prothena Corporation PLC (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) G72800108 (CUSIP Number) Diana L. Hayes, Esq. Trenam Law 2700 Bank of America Plaza Tampa, Florida 33602 8
February 14, 2023	SC 13G/A	PRTA / Prothena Corp plc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment SC 13G/A 1 prta13gadec22.txt UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) PROTHENA CORP PLC (Name of Issuer) COMMON STOCK (Title of Class of Securities) G72800108 (CUSIP NUMBER) December 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursu
February 9, 2023	SC 13G/A	PRTA / Prothena Corp plc / FMR LLC Passive Investment SC 13G/A 1 filing.txt SCHEDULE 13G Amendment No.1 PROTHENA CORP PLC COMMON STOCK Cusip #G72800108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G72800108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 3,946,661 Item 6: 0 Item 7: 3,947,272 Item 8: 0 Item 9: 3
February 1, 2023	SC 13G/A	PRTA / Prothena Corp plc / BlackRock Inc. Passive Investment SC 13G/A 1 ie00b91xrn20013123.txt ie00b91xrn20013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 8) PROTHENA CORPORATION PUBLIC LIMITED COMPANY - (Name of Issuer) Common Stock - (Title of Class of Securities) B91XRN2 - (SEDOL Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Ch
December 16, 2022	424B5	3,250,000 Shares Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254622 3,250,000 Shares Ordinary Shares Prothena Corporation plc is offering 3,250,000 of its ordinary shares. Our ordinary shares are listed on the Nasdaq Global Select Market under the symbol ?PRTA.? The closing price of our ordinary shares on the Nasdaq Global Select Market on December 14, 2022 was $57.97 per ordinary share
December 16, 2022	EX-1.1	Underwriting Agreement dated December 14, 2022 by and among Prothena Corporation plc and the Representatives EX-1.1 2 d378186dex11.htm EX-1.1 Exhibit 1.1 PROTHENA CORPORATION PLC (an Irish public limited company) 3,250,000 Ordinary Shares UNDERWRITING AGREEMENT Dated: December 14, 2022 PROTHENA CORPORATION PLC (an Irish public limited company) 3,250,000 Ordinary Shares ($0.01 nominal value per share) UNDERWRITING AGREEMENT December 14, 2022 Jefferies LLC Evercore Group L.L.C. Cantor Fitzgerald & Co. as R
December 16, 2022	EX-FILING FEES	Calculation of Filing Fee Tables (Form Type) Prothena Corporation plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Ru Exhibit 107 Calculation of Filing Fee Tables 424(b)(5) (Form Type) Prothena Corporation plc (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(1) Carry Forward Form Type Carry Forward File Number Carry Forward Initial effective date Filing Fee Previously Paid In Connection with Unsold Securities to be Carried Forward Fees to Be Paid Equity Ordinary Shares, $0.
December 16, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or other jurisdiction of incor
December 13, 2022	424B5	SUBJECT TO COMPLETION, DATED DECEMBER 13, 2022 PRELIMINARY PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED MARCH 23, 2021 3,000,000 Shares Ordinary Shares 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254622 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell nor do they seek an offer to buy these securities in any jurisdiction where the offer or sale
November 21, 2022	EX-99.1	Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy EXHIBIT 99.1 PRESS RELEASE Prothena Announces Achievement of $40 Million Clinical Milestone Payment from Novo Nordisk for PRX004/NNC6019 Under Investigation for the Treatment of ATTR Cardiomyopathy ?Prothena is eligible to receive development and sales milestone payments from Novo Nordisk totaling up to $1.2 billion, including $100 million announced to date ?PRX004/NNC6019 continues to advance in
November 21, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
November 3, 2022	EX-10.4	, between Prothena Biosciences Inc and Dennis J. Selkoe Exhibit 10.4 CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?) is effective as of October 1, 2022 (the ?Effective Date?) and is made by and between Dennis J. Selkoe, M.D., an individual (?Consultant?), and Prothena Biosciences Inc, a Delaware corporation with offices at 331 Oyster Point Boulevard, South San Francisco, CA 94080, U.S.A. (?Prothena?). Consultant and Prothena may each
November 3, 2022	EX-99.1	September 30, December 31, 2021 2022 2021 Assets Cash and cash equivalents $ 495,628 $ 579,094 Prepaid expenses and other current assets 28,934 5,715 Total current assets 524,562 584,809 Property and equipment, net 1,997 2,012 Operating lease right-o Exhibit 99.1 Prothena Reports Third Quarter 2022 Financial Results and Business Highlights ?Net cash used in operating and investing activities was $31.3 million in the third quarter and $104.2 million for the first nine months of 2022; quarter-end cash and restricted cash position was $497.0 million ?Phase 3 VITAL study data on observed survival benefit in Mayo Stage IV AL amyloidosis patients tr
November 3, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COM
November 3, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorp
October 31, 2022	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorp
September 1, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 30, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpo
August 10, 2022	EX-4.9	Twelfth Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan Exhibit 4.9 TWELFTH AMENDMENT TO THE PROTHENA CORPORATION PLC 2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN This Twelfth Amendment (this ?Twelfth Amendment?) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (?2020 EIIP?), was made and adopted by the Board of Directors (?Board?) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the ?Comp
August 10, 2022	EX-4.10	Thirteenth Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan Exhibit 4.10 THIRTEENTH AMENDMENT TO THE PROTHENA CORPORATION PLC 2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN This Thirteenth Amendment (this ?Thirteenth Amendment?) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (?2020 EIIP?), was made and adopted by the Board of Directors (?Board?) of Prothena Corporation plc, a public limited company organized under the laws of Ireland
August 10, 2022	EX-4.8	Eleventh Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan Exhibit 4.8 ELEVENTH AMENDMENT TO THE PROTHENA CORPORATION PLC 2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN This Eleventh Amendment (this ?Eleventh Amendment?) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (?2020 EIIP?), was made and adopted by the Board of Directors (?Board?) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the ?C
August 10, 2022	EX-FILING FEES	Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Prothena Corporation Public Limited Company (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity (2) Ordinary Shares, par value $0.
August 10, 2022	S-8	As filed with the Securities and Exchange Commission on August 10, 2022 As filed with the Securities and Exchange Commission on August 10, 2022 Registration No.
August 10, 2022	SC 13G/A	PRTA / Prothena Corp plc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) PROTHENA CORP PLC (Name of Issuer) COMMON STOCK (Title of Class of Securities) G72800108 (CUSIP NUMBER) July 31, 2022 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedule is fil
August 8, 2022	EX-99.1	June 30, December 31, 2021 2022 2021 Assets Cash and cash equivalents $ 508,795 $ 579,094 Prepaid expenses and other current assets 12,499 5,715 Total current assets 521,294 584,809 Property and equipment, net 1,861 2,012 Operating lease right-of-use Exhibit 99.1 Prothena Reports Second Quarter 2022 Financial Results and Business Highlights ?Net cash used in operating and investing activities was $35.5 million in the second quarter and $72.9 million for the first six months of 2022; quarter-end cash and restricted cash position was $510.1 million ?Broad Alzheimer?s disease portfolio continues to advance: FDA Fast Track designation granted in A
August 8, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMPANY
August 8, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpor
June 27, 2022	SC 13G	PRTA / Prothena Corp plc / SCULLY WILLIAM P - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) * Prothena Corporation PLC (Name of Issuer) Ordinary Shares, $0.01 par value (Title of Class of Securities) G72800108 (CUSIP Number) Diana L. Hayes, Esq. Trenam Law 2700 Bank of America Plaza Tampa, Florida 33602 813-227-7433 (Name, Address and Telephone N
May 20, 2022	EX-10.1	Third Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan Exhibit 10.1 THIRD AMENDMENT TO THE PROTHENA CORPORATION PLC 2018 LONG TERM INCENTIVE PLAN This Third Amendment (this ?Third Amendment?) to the Prothena Corporation plc 2018 Long Term Incentive Plan, as amended (?2018 LTIP?), was made and adopted by the Board of Directors (?Board?) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the ?Company?), on Februar
May 20, 2022	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 17, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 5, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ DEFA14A 1 d338243ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule
May 5, 2022	EX-99.1	March 31, December 31, 2021 2022 2021 Assets Cash and cash equivalents $ 542,994 $ 579,094 Prepaid expenses and other current assets 12,626 5,715 Total current assets 555,620 584,809 Property and equipment, net 1,865 2,012 Operating lease right-of-us Exhibit 99.1 Prothena Reports First Quarter 2022 Financial Results and Business Highlights •Net cash used in operating and investing activities was $37.4 million in the first quarter; quarter-end cash and restricted cash position was $544.3 million •Advanced PRX012, a potential best-in-class, subcutaneous treatment for Alzheimer’s disease, into a Phase 1 clinical study and received FDA Fast Track
May 5, 2022	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMPANY
May 5, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporati
April 26, 2022	EX-99.1	Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease EX-99.1 2 exhibit991prx012fasttrackp.htm EX-99.1 EXHIBIT 99.1 Prothena Receives FDA Fast Track Designation for PRX012, a Next-Generation Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease •PRX012 is a potential best-in-class, subcutaneous anti-amyloid beta antibody therapy currently in a Phase 1 clinical study for the treatment of Alzheimer’s disease DUBLIN, Ir
April 26, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpor
April 25, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State
March 31, 2022	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 DEF 14A 1 ny20001664x2def14a.htm DEF 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only
March 31, 2022	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Ame UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide
March 28, 2022	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpor
March 28, 2022	EX-99.1	Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer’s Disease EXHIBIT 99.1 Prothena Announces FDA Clearance of IND for PRX012, a Subcutaneous Anti-Amyloid Beta Antibody Under Investigation for the Treatment of Alzheimer?s Disease ?Prothena has initiated Phase 1 SAD study of PRX012, under investigation for the treatment of Alzheimer?s disease DUBLIN, Ireland, March 28, 2022 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical company with a robust
March 25, 2022	8-K	Regulation FD Disclosure UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpor
March 11, 2022	PRE 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? ? ? ? ? Filed by a Party other than the Registrant ? ? ?? Check the appropriate box: ? Preliminary Proxy Statement ?? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6
March 1, 2022	SC 13G	PRTA / Prothena Corp plc / First Light Asset Management, LLC - SCHEDULE FILED TO REPORT ACQUISITION OF BENEFICIAL OWNERSHIP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934* Prothena Corporation, PLC (Name of Issuer) Common Stock, $0.01 par value (Title of Class of Securities) G72800108 (CUSIP Number) February 28, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
February 25, 2022	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the year ended December 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 001-35676 PROTHENA CORPORATION PUB
February 25, 2022	EX-4.2	Description of Registrant’s Securities EXHIBIT 4.2 DESCRIPTION OF REGISTRANT?S SECURITIES This description is summarized from, and qualified in its entirety by reference to, our Amended and Restated Memorandum and Articles of Association (our ?Constitution?), each of which are incorporated by reference as exhibits to the Annual Report on Form 10-K of which this exhibit is a part. In this exhibit, unless the context otherwise requires,
February 25, 2022	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Subsidiary Name Jurisdiction of Incorporation or Organization Prothena Biosciences Limited Ireland Prothena Biosciences Inc Delaware Prothena Finance Inc Delaware Othair Prothena Limited Ireland Prothena Pharma Limited Ireland
February 25, 2022	EX-10.20	First through Eleventh Amendments to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan Exhibit 10.20 FIRST AMENDMENT TO THE PROTHENA CORPORATION PLC 2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN This First Amendment (this ?First Amendment?) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (?2020 EIIP?), was made and adopted by the Board of Directors (?Board?) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the ?Company?
February 17, 2022	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 17, 2022 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
February 17, 2022	EX-99.1	December 31, 2021 2020 Assets Cash and cash equivalents $ 579,094 $ 295,380 Accounts receivable — 15 Prepaid expenses and other current assets 5,715 2,537 Restricted cash, current — 1,352 Total current assets 584,809 299,284 Property and equipment, n Exhibit 99.1 Prothena Reports Fourth Quarter and Full Year 2021 Financial Results, and Provides Financial Guidance and Business Highlights ?Net cash used in operating and investing activities was $22.8 million in the fourth quarter and net cash provided by operating and investing activities was $92.0 million for the full year 2021; quarter-end cash and restricted cash position was $580.4 million ?
February 14, 2022	SC 13G/A	PRTA / Prothena Corp plc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) PROTHENA CORP PUBLIC LTD CO (Name of Issuer) COMMON STOCK (Title of Class of Securities) G72800108 (CUSIP NUMBER) December 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this S
February 9, 2022	SC 13G	PRTA / Prothena Corp plc / FMR LLC Passive Investment SCHEDULE 13G Amendment No. 0 PROTHENA CORP PLC COMMON STOCK Cusip #G72800108 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: [x] Rule 13d-1(b) [ ] Rule 13d-1(c) [ ] Rule 13d-1(d) Cusip #G72800108 Item 1: Reporting Person - FMR LLC Item 2: (a) [ ] (b) [ ] Item 4: Delaware Item 5: 841,958 Item 6: 0 Item 7: 2,641,741 Item 8: 0 Item 9: 2,641,741 Item 11: 5.669
February 3, 2022	SC 13G/A	PRTA / Prothena Corp plc / BlackRock Inc. Passive Investment ie00b91xrn20020322.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 7) PROTHENA CORPORATION PLC - (Name of Issuer) Common Stock - (Title of Class of Securities) B91XRN2 - (SEDOL Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuan
January 14, 2022	SC 13D/A	PRTA / Prothena Corp plc / EcoR1 Capital, LLC Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Prothena Corporation Public Limited Company (Name of Issuer) Ordinary Shares, par value $0.01 per share (Title of Class of Securities) G72800108 (CUSIP Number) James J. Frolik, Esq. Anthony J. Caldwell, Esq. Shartsis Friese LLP One Maritime Plaza, 18th Fl
December 23, 2021	EX-1.1	Distribution Agreement, dated December 23 2021, by and among the Company, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated, Cantor Fitzgerald & Co., RBC Capital Markets, LLC, and JMP Securities LLC. Exhibit 1.1 PROTHENA CORPORATION PLC EQUITY DISTRIBUTION AGREEMENT December 23, 2021 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 CANTOR FITZGERALD & CO. 499 Park Avenue, 6th Floor New York, New York 10022 RBC CAPITAL MARKETS, LLC 200 Vesey Street New York, New
December 23, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 23, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incor
December 23, 2021	424B5	CALCULATION OF REGISTRATION FEE Title of Securities Being Registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Ordinary Shares, par value $0.01 per share $250,000,000 $23,175 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254622 CALCULATION OF REGISTRATION FEE Title of Securities Being Registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Ordinary Shares, par value $0.01 per share $250,000,000 $23,175 (1) The proposed maximum aggregate offering price is being used to calculate the registration fee pursuant to Rul
November 4, 2021	EX-10.2	Amended and Restated Consulting Agreement, dated July 15, 2020, between Prothena Biosciences Inc and Dennis J. Selkoe Exhibit 10.2 AMENDED AND RESTATED CONSULTING AGREEMENT This Amended and Restated Consulting Agreement (this ?Agreement?) is effective as of July 15, 2020 (the ?Effective Date?) and is made by and between Dennis J. Selkoe, M.D., an individual (?Consultant?), and Prothena Biosciences Inc, a Delaware corporation with offices at 331 Oyster Point Boulevard, South San Francisco, CA 94080, U.S.A. (?Proth
November 4, 2021	EX-99.1	September 30, December 31, 2021 2020 Assets Cash and cash equivalents $ 600,098 $ 295,380 Accounts receivable 79 15 Prepaid expenses and other current assets 7,353 2,537 Restricted cash, current — 1,352 Total current assets 607,530 299,284 Property a Exhibit 99.1 Prothena Reports Third Quarter 2021 Financial Results and Business Highlights ?Net cash provided by operating and investing activities was $111.9 million in the third quarter and $114.8 million for the first nine months of 2021; Quarter-end cash and restricted cash position was $601.5 million ?Received $140 million from partner payments in third quarter from Novo Nordisk and Bristol M
November 4, 2021	EX-10.4	Share Purchase Agreement, dated as of July 8, 2021, by and among Novo Nordisk A/S, Novo Nordisk Region Europe A/S, Prothena Corporation plc, and Prothena Biosciences Limited Exhibit 10.4 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both not material and the type of information that the registrant customarily and actually treats as private and confidential. SHARE PURCHASE AGREEMENT by and between NOVO NORDISK A/S; NOVO NORDISK REGION EUROPE A/S; PROTHENA CORPORATION PLC; and PROTH
November 4, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30,2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMP
November 4, 2021	EX-10.5	U.S. License Agreement, dated as of July 30, 2021, as amended on August 12, 2021 and September 8, 2021, by and between Prothena Biosciences Limited and Celgene Switzerland LLC [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).
November 4, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorp
November 4, 2021	EX-10.3	Amendment No. 2 to License, Development, and Commercialization Agreement, entered into on August 26, 2021, among Prothena Biosciences Limited, Prothena Biosciences Inc, F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc. Exhibit 10.3 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is both not material and the type of information that the registrant customarily and actually treats as private and confidential. AMENDMENT NO. 2 TO LICENSE, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENT This AMENDMENT NO. 2 (this ?Amendment No. 2?) is mad
November 4, 2021	EX-10.1	Tenth Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan Exhibit 10.1 TENTH AMENDMENT TO THE PROTHENA CORPORATION PLC 2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN This Tenth Amendment (this ?Tenth Amendment?) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (?2020 EIIP?), was made and adopted by the Board of Directors (?Board?) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the ?Company?)
October 1, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Inco
August 6, 2021	S-8	As filed with the Securities and Exchange Commission on August 6, 2021 As filed with the Securities and Exchange Commission on August 6, 2021 Registration No.
August 5, 2021	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMPANY
August 5, 2021	EX-10.2	Eighth Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan Exhibit 10.2 EIGHTH AMENDMENT TO THE PROTHENA CORPORATION PLC 2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN This Eighth Amendment (this ?Eighth Amendment?) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (?2020 EIIP?), was made and adopted by the Board of Directors (?Board?) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the ?Compan
August 5, 2021	EX-99.1	June 30, December 31, 2021 2020 Assets Cash and cash equivalents $ 399,831 $ 295,380 Accounts receivable 3 15 Prepaid expenses and other current assets 8,282 2,537 Restricted cash, current 1,352 1,352 Total current assets 409,468 299,284 Property and Exhibit 99.1 Prothena Reports Second Quarter 2021 Financial Results and Business Highlights ?Net cash provided by operating and investing activities was $36.6 million in the second quarter and $2.9 million for the first six months of 2021; quarter-end cash and restricted cash position of $402.5 million (includes $60 million payment from Roche) provides additional funding to continue advancing R&D
August 5, 2021	EX-10.3	Ninth Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan Exhibit 10.3 NINTH AMENDMENT TO THE PROTHENA CORPORATION PLC 2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN This Ninth Amendment (this ?Ninth Amendment?) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (?2020 EIIP?), was made and adopted by the Board of Directors (?Board?) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the ?Company?)
August 5, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpor
August 3, 2021	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 30, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpora
July 12, 2021	8-K	Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 8, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
July 12, 2021	EX-99.1	Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena’s ATTR Amyloidosis Programme EXHIBIT 99.1 Prothena and Novo Nordisk Announce Acquisition Agreement for Prothena?s ATTR Amyloidosis Programme ?Prothena is eligible to receive development and sales milestone payments totalling up to 1.2 billion US dollars, including 100 million dollars in upfront and near-term clinical milestone payments ?Novo Nordisk will develop the phase 2-ready antibody PRX004 for the rare heart disease ATT
June 24, 2021	EX-99.1	Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration EXHIBIT 99.1 Prothena Announces Bristol Myers Squibb Opt-in of Anti-Tau PRX005 as the First Program from Global Neuroscience Research and Development Collaboration ?Prothena to receive $80 million from Bristol Myers Squibb for exclusive US license to PRX005; Next option for worldwide rights following completion Phase 1 ?PRX005 is an investigational best-in-class anti-tau antibody targeting the mic
June 24, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpora
June 10, 2021	SC 13G	PRTA / Prothena Corp plc / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) PROTHENA CORP PUBLIC LTD CO (Name of Issuer) COMMON STOCK (Title of Class of Securities) G72800108 (CUSIP NUMBER) May 31, 2021 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Schedul
May 28, 2021	EX-1.1	Distribution Agreement, dated May 28, 2021, by and among the Company, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated, Cantor Fitzgerald & Co., RBC Capital Markets, LLC, and Raymond James & Associates, Inc. Exhibit 1.1 PROTHENA CORPORATION PLC EQUITY DISTRIBUTION AGREEMENT May 28, 2021 PIPER SANDLER & CO. U.S. Bancorp Center 800 Nicollet Mall Minneapolis, Minnesota 55402 STIFEL, NICOLAUS & COMPANY, INCORPORATED One South Street, 15th Floor Baltimore, Maryland 21202 CANTOR FITZGERALD & CO. 499 Park Avenue, 6th Floor New York, New York 10022 RBC CAPITAL MARKETS, LLC 200 Vesey Street New York, New York
May 28, 2021	424B5	CALCULATION OF REGISTRATION FEE Title of Securities Being Registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Ordinary Shares, par value $0.01 per share $100,000,000 $10,910.00 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254622 CALCULATION OF REGISTRATION FEE Title of Securities Being Registered Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Ordinary Shares, par value $0.01 per share $100,000,000 $10,910.00 (1) The proposed maximum aggregate offering price is being used to calculate the registration fee pursuant to
May 28, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 28, 2021	8-K	Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 21, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 21, 2021	EX-10.1	Second Amendment to the Prothena Corporation plc 2018 Long Term Incentive Plan Exhibit 10.1 SECOND AMENDMENT TO THE PROTHENA CORPORATION PLC 2018 LONG TERM INCENTIVE PLAN This Second Amendment (this ?Second Amendment?) to the Prothena Corporation plc 2018 Long Term Incentive Plan, as amended (?2018 LTIP?), was made and adopted by the Board of Directors (?Board?) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the ?Company?), on Febr
May 20, 2021	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 18, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 11, 2021	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorporat
May 11, 2021	EX-99.1	March 31, December 31, 2021 2020 Assets Cash and cash equivalents $ 342,993 $ 295,380 Accounts receivable 1 15 Prepaid expenses and other current assets 7,955 2,537 Restricted cash, current 1,352 1,352 Total current assets 352,301 299,284 Property an Exhibit 99.1 Prothena Reports First Quarter 2021 Financial Results, and Provides Updated Financial Guidance and R&D Update ?Net cash used in operating and investing activities was $33.7 million in the first quarter; quarter-end cash and restricted cash position of $345.7 million provides funding to advance the R&D pipeline ?Announced confirmatory Phase 3 AFFIRM-AL study of birtamimab in Mayo Stage
May 11, 2021	EX-10.1	Offer Letter, dated March 18, 2021, between Prothena Biosciences Inc and Hideki Garren Exhibit 10.1 Hideki Garren [Address Redacted] REVISED ? March 18, 2021 Dear Hideki: I am pleased to confirm this offer for you to join Prothena Biosciences Inc (?Prothena? or the ?Company?). We are confident in your knowledge, expertise and judgment, and believe your performance will meet our team?s high-quality objectives and standards. Your start date will be April 5, 2021, and the Prothena Corp
May 11, 2021	10-Q	Quarterly Report - 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 001-35676 PROTHENA CORPORATION PUBLIC LIMITED COMPANY
May 11, 2021	EX-10.2	Seventh Amendment to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan Exhibit 10.2 SEVENTH AMENDMENT TO THE PROTHENA CORPORATION PLC 2020 EMPLOYMENT INDUCEMENT INCENTIVE PLAN This Seventh Amendment (this ?Seventh Amendment?) to the Prothena Corporation plc 2020 Employment Inducement Incentive Plan (?2020 EIIP?), was made and adopted by the Board of Directors (?Board?) of Prothena Corporation plc, a public limited company organized under the laws of Ireland (the ?Com
April 20, 2021	CT ORDER	- begin 644 filename1 M)5!$1BTQ+C8-)>+CS],-"C0V(# @;V)J#3P\+TQI;F5A(7)L&(IEE M@"1C?0J0+\':!K0EKT@<: J%/( ^.
March 31, 2021	DEF 14A	Definitive Proxy Statement TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? ? ? ? ? Filed by a Party other than the Registrant ? ? ? Check the appropriate box: ? Preli
March 31, 2021	DEFA14A	- DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confide
March 26, 2021	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2021 PROTHENA CORPORATION PUBLIC LIMITED COMPANY (Exact name of registrant as specified in its charter) Ireland 001-35676 98-1111119 (State or Other Jurisdiction of Incorpor
March 26, 2021	EX-1.1	Underwriting Agreement, dated March 23, 2021, by and among Prothena Corporation plc and Citigroup Global Markets Inc., Jefferies LLC, and Cantor Fitzgerald & Co. Exhibit 1.1 PROTHENA CORPORATION PLC (an Irish public limited company) 3,500,000 Ordinary Shares UNDERWRITING AGREEMENT Dated: March 23, 2021 PROTHENA CORPORATION PLC (an Irish public limited company) 3,500,000 Ordinary Shares ($0.01 nominal value per share) UNDERWRITING AGREEMENT March 23, 2021 Citigroup Global Markets Inc. Jefferies LLC Cantor Fitzgerald & Co. as Representatives of the several U
March 24, 2021	424B5	Title of Securities Being Registered Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254622 Title of Securities Being Registered Amount to be Registered Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Amount of Registration Fee(1) Ordinary Shares, par value $0.01 per share 4,025,000 shares(2) $20.75 $83,518,750 $9,111.90 (1) Calculated in accordance with Rule 457(r) under th
March 23, 2021	S-3ASR	- S-3ASR Table of Contents As filed with the Securities and Exchange Commission on March 23, 2021 Registration No.
March 23, 2021	424B5	SUBJECT TO COMPLETION, DATED MARCH 23, 2021 PRELIMINARY PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED MARCH 23, 2021 Ordinary Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-254622 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell nor do they seek an offer to buy these securities in any jurisdiction where the offer or sale is no
March 15, 2021	PRE 14A	- PRE 14A TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ??) Filed by the Registrant ? ? ? ? ? Filed by a Party other than the Registrant ? ? ?? Check the appropriate box: ? Prel
February 26, 2021	EX-21.1	List of Subsidiaries Exhibit 21.1 List of Subsidiaries Subsidiary Name Jurisdiction of Incorporation or Organization Prothena Biosciences Limited Ireland Prothena Biosciences Inc Delaware Prothena Finance Inc Delaware Neotope Neuroscience Limited Ireland Othair Prothena Limited Ireland

GB:0Y3M	10,03 $
DE:0PT	8,61 €

PRTA / Prothena Corporation plc - SEC-Einreichungen, Jahresbericht, Proxy Statement

Basisstatistiken

SEC Filings

SEC Filings (Chronological Order)

How Much do you Like Fintel?

Write a Review and get 25% Off Your Next Purchase

How can we Improve?

Other Listings